Glamcyst-M Tablet SR is a sustained-release formulation combining Metformin 500 mg and Myo-Inositol 600 mg, designed to manage metabolic and reproductive disturbances commonly associated with polycystic ovary syndrome (PCOS) and insulin resistance. Metformin, a biguanide antihyperglycemic agent, improves insulin sensitivity by reducing hepatic glucose production and enhancing peripheral glucose uptake, thereby aiding in glycemic control and reducing hyperinsulinemia. Myo-Inositol, a naturally occurring isomer of inositol, plays a crucial role in insulin signal transduction and ovarian function, promoting ovulation and restoring hormonal balance. The sustained-release mechanism of Glamcyst-M ensures gradual drug release, improving patient compliance by minimizing gastrointestinal side effects often linked with immediate-release metformin. This combination therapy addresses both metabolic and reproductive aspects of PCOS, contributing to improved menstrual regularity, reduced androgen levels, and enhanced ovulatory function. Glamcyst-M Tablet SR is indicated for patients with insulin resistance, impaired glucose tolerance, and PCOS-related infertility. It should be used under medical supervision, with dosage adjustments based on clinical response and tolerability. Contraindications include renal impairment, hepatic dysfunction, and hypersensitivity to any component. Regular monitoring of blood glucose, renal function, and liver enzymes is recommended during therapy.